Focus Diagnostics Home
 Home  About Focus Diagnostics  Employment  Contact Us
USA International Certifications Customer Service Account Setup Contact Us Compliance Commitment
Kit Description Photo Guide Schematic FAQ Back to Product List
IF0700 Epstein-Barr Virus (EBV) Early Antigen IFA
Indirect immunofluorescent antibody (IFA) test for the detection and semi-quantitation of human serum IgG antibodies to Epstein-Barr virus early antigens, both restricted (R) and diffuse (D). Each kit contains ten 12-well slides, sample diluent, conjugate, and positive and negative controls.
 
  open pdf document Package Inserts
 

EBV Early Antigen

Slide 1 Slide 2
IgG Positive Sample IgG Negative Sample
[Picture of EBV Early slide] [Picture of EBV Early  slide]

 

Back to Top
 

EBV Early Antigen IFA Slide Schematic


Back to Top
Frequently Asked Questions (FAQ)
Q: The cells on this IFA slide all appear positive. Is this possible?

A: If all the cells are positive this is likely to be some type of an anti-cellular reaction. The percent positive should be approximately the same as seen with the positive control.

Q: When only two or three cells are seen fluorescing is this a positive?

A: No, the percent of positive cells seen should be at least as high as the number of positive cells seen with the positive control at its endpoint.



Q: Why is the positive control for this IFA kit barely positive at the screening dilution?

A: The positive controls are bottled at the screening dilution and can be titered for an endpoint from this dilution. The control should be used in the first well without further dilution.



Q: Is it possible to differentiate the restricted and diffuse antigen using these slides?

A: The EA slides do not differentiate between the two types of antigen.



Q: Why does this kit have a sample diluent?

A: During the development of this kit it was found that a diluent improved the readability of the slides and decreased the non-specific reactivity.

Back to Top
Epstein-Barr Virus (EBV) Early Antigen IFA
       
Back to Product List  
       
First FDA Clearance of a 2009 H1N1 Test Given to Focus Diagnostics


FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics’ Focus Diagnostics


Focus Diagnostics provides the first commercial test for detecting the 2009 H1N1 influenza virus that the FDA has authorized for emergency use.


 
©2010 - Focus Diagnostics - All Rights Reserved - Site Revision ID: WEB.FOCUSDX.C3 - Privacy Policy - Site Map